News from daiichi sankyo, inc A wide array of domestic and global news stories; news topics include politics / government, business, technology, religion, sports/entertainment, science/nature, and health/lifestyle. Articles that appear in this section may be written in English or other languages, as well.

Sep 03, 2014, 07:47 ET

Daiichi Sankyo utvider TaNeDS Collaborative Drug Discovery-programmet i Europa

TOKYO, 1 september 2014 /PRNewswire/ - Daiichi Sankyo Company, Limited (Tokyo-børsen: 4568, heretter Daiichi Sankyo) kunngjorde 1....

Sep 03, 2014, 03:04 ET

Daiichi Sankyo öffnet kollaboratives Arzneimittelforschungsprogramm TaNeDS in Europa für weitere Länder

Daiichi Sankyo Company Limited (Tokioter Börse: 4568; im Folgenden „Daiichi Sankyo") veröffentlichte am 1. September nähere...

Sep 03, 2014, 03:03 ET

Daiichi Sankyo amplía el programa colaborador de descubrimiento de fármacos TaNeDS en Europa

Daiichi Sankyo Company, Limited (Bolsa de Valores de Tokio: 4568; de aquí en adelante Daiichi Sankyo), anunció el 1 de septiembre los...

Sep 02, 2014, 11:50 ET
PREvention oF thromboembolic events - European Registry in Atrial Fibrillation (PREFER in AF)

One Year Data from the PREFER in AF Registry Show Significant Changes in Atrial Fibrillation (AF) Management in Europe and Implementation of Clinical Guidelines

Registry provides new insights into AF treatment decisions, including patients' quality of life and treatment satisfaction[1],[2] ESC...

Sep 02, 2014, 09:00 ET

Subgroup Analysis of ENGAGE AF-TIMI 48 Explores the Relationship Between Edoxaban Dose, Concentration, Anti-Factor Xa Activity and Outcomes

 Daiichi Sankyo Company, Limited (hereafter, Daiichi Sankyo) today announced data from a subgroup analysis of the phase 3 ENGAGE AF-TIMI 48...

Sep 02, 2014, 08:57 ET

Daiichi Sankyo étend son programme collaboratif de découverte médicamenteuse TaNeDS en Europe

Daiichi Sankyo Company, Limited (Bourse de Tokyo : 4568 ; ci-après désignée Daiichi Sankyo) a annoncé le 1er...

Aug 31, 2014, 22:00 ET

Daiichi Sankyo Further Expands TaNeDS Collaborative Drug Discovery Program in Europe

Daiichi Sankyo Company, Limited (Tokyo Stock Exchange: 4568; hereafter Daiichi Sankyo) announced on September 1 details of the application for its...

Aug 31, 2014, 08:38 ET

Global Survey of Cardiologists Highlights Complexity of Managing Non-Valvular Atrial Fibrillation and Reinforces Need for Individualized Approach to Patient Care

Daiichi Sankyo and the Heart Rhythm Society today announced results from a global survey, which polled cardiologists from around the world and...

Aug 06, 2014, 19:00 ET
Daiichi Sankyo Logo. (PRNewsFoto/Daiichi Sankyo, Inc.)

Daiichi Sankyo and Charleston Laboratories Announce Collaboration to Develop and Commercialize Novel, Fixed-Dose Combination Hydrocodone Products for Pain and Opioid-Induced Nausea and Vomiting (OINV) in the US

Daiichi Sankyo and Charleston Laboratories, Inc., through its wholly owned subsidiary LOCL Pharma, Inc., announced today that the parties have...

May 16, 2014, 07:33 ET

Journée Mondiale de l'Hypertension 2014 : Daiichi Sankyo fait du bien à votre cœur !

  - La Journée Mondiale de l'Hypertension a lieu chaque année le 17 mai. Le thème choisi pour 2014 est "Connaître...

May 15, 2014, 09:54 ET

Giornata Mondiale contro l'Ipertensione Arteriosa 2014

Daiichi Sankyo e "Little Hearts" insieme per gli orfani dell'Est Europa  Il 17 maggio ricorre la decima edizione della Giornata Mondiale...

May 15, 2014, 08:50 ET

Daiichi Sankyo pone en marcha la iniciativa "Haz que tu corazón se sienta bien"

Daiichi Sankyo pone en marcha la iniciativa "Haz que tu corazón se sienta bien" -...

Apr 18, 2014, 09:00 ET

Ken Keller Named President, US Commercial, Daiichi Sankyo, Inc.

 Daiichi Sankyo, Inc. announced today that Ken Keller will join the company as President of its Commercial operations in the United States...

Apr 02, 2014, 07:00 ET

Daiichi Sankyo extends the PREFER in AF patient registry to provide additional insights into the long-term management of patients with atrial fibrillation

For European Media Only, Not for UK Media   Atrial fibrillation (AF) is the most common heart rhythm disorder[1] resulting in a...

Mar 31, 2014, 07:00 ET

Daiichi Sankyo Initiates Phase 3 ENSURE-AF Study, Investigating Once-Daily Edoxaban in Patients with Atrial Fibrillation Undergoing Cardioversion

Daiichi Sankyo Company, Limited (hereafter, Daiichi Sankyo) today announced that it has started enrolling patients into the ENSURE-AF multinational...

Mar 24, 2014, 07:00 ET

Once-Daily Edoxaban Evaluated in Two Subgroup Analyses of East Asian Patients from the Largest Comparative Phase 3 Trials of a Novel Oral Anticoagulant

 Daiichi Sankyo Company, Limited (hereafter, Daiichi Sankyo) today announced late-breaking data from two pre-specified subgroup analyses of...

Jan 08, 2014, 12:29 ET
Jan 08, 2014, 08:30 ET

Daiichi Sankyo, Virtici and Celdara Medical Announce Collaboration to Identify and Progress High Potential Therapeutics

Daiichi Sankyo, Co., Ltd., Virtici, LLC and Celdara Medical, LLC announced today that they have entered into a collaboration to jointly...

Jan 07, 2014, 11:09 ET
Dec 19, 2013, 07:04 ET

Daiichi Sankyo Submits Supplemental New Drug Application in Japan for LIXIANA® (Edoxaban Tosilate Hydrate) for New Indications

Daiichi Sankyo Company, Limited (hereafter, Daiichi Sankyo) today announced that it has submitted a supplemental New Drug Application (NDA) for its...